EFFICACY AND SAFETY OF BARICITINIB IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS AT 12 WEEKS

被引：0
|
作者：
Tanaka, Y. [1 ]
Emoto, K. [2 ]
Tsujimoto, M. [2 ]
Schlichting, D. [3 ]
Macias, W. [3 ]
机构：
[1] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[2] Eli Lilly Japan KK, Kobe, Hyogo, Japan
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1366
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0149
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study
    Tanaka, Yoshiya
    Ishii, Taeko
    Cai, Zhihong
    Schlichting, Douglas
    Rooney, Terence
    Macias, William
    MODERN RHEUMATOLOGY, 2018, 28 (01) : 20 - 29
  • [22] Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis
    Lee, Young Ho
    Song, Gwan Gyu
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (08): : 785 - 796
  • [23] Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis
    Iwamoto, Naoki
    Tsuji, Sosuke
    Takatani, Ayuko
    Shimizu, Toshimasa
    Fukui, Shoichi
    Umeda, Masataka
    Nishino, Ayako
    Horai, Yoshiro
    Koga, Tomohiro
    Kawashiri, Shin-ya
    Aramaki, Toshiyuki
    Ichinose, Kunihiro
    Hirai, Yasuko
    Tamai, Mami
    Nakamura, Hideki
    Terada, Kaoru
    Origuchi, Tomoki
    Eguchi, Katsumi
    Ueki, Yukitaka
    Kawakami, Atsushi
    PLOS ONE, 2017, 12 (05):
  • [24] Efficacy and Safety of Baricitinib in B/tsDMARDs Naive and B/tsDMARDs-IR Patients with Rheumatoid Arthritis
    Yamasaki, Masaomi
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3554 - 3556
  • [25] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 31 - 31
  • [26] Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
    Zhang, Xin
    Chua, Laiyi
    Ernest, C. Steven, II
    Macias, William
    Rooney, Terence
    San Tham, Lai
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [27] SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS
    Genovese, M.
    Smolen, J.
    Takeuchi, T.
    Hyslop, D.
    MacIas, W.
    Rooney, T.
    Chen, L.
    Dickson, C.
    Riddle, J.
    Cardillo, T.
    Winthrop, K.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 28 - 28
  • [28] RESPONSE TO BARICITINIB AT 4 WEEKS PREDICTS RESPONSE AT 12 AND 24 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
    Weinblatt, M.
    Taylor, P.
    Tanaka, Y.
    Keystone, E.
    Schiff, M.
    Fleischmann, R.
    Yang, L.
    Arora, V.
    de Bono, S.
    Holzkaemper, T.
    Schlichting, D.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 255 - 256
  • [29] Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis
    Kremer, Joel M.
    Genovese, Mark C.
    Muram, David
    Zhong, Jinglin
    Alam, Jahangir
    Schiff, Michael
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [30] RESPONSE TO BARICITINIB AT 4 WEEKS PREDICTS RESPONSE AT 12 AND 24 WEEKS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM TWO PHASE THREE STUDIES
    Joel, Kremer
    Maxime, Dougados
    Mark, Genovese C.
    Paul, Emery
    Yang Lili
    Stephanie, De Bono
    Thorsten, Holzkaemper
    Douglas, Schlichting E.
    Josef, Smolen S.
    Stephen, Hall
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 28 - 28
12345